Stock Events

CytoMed Therapeutics 

€1.97
0
+€0+0% Friday 13:29

Statistics

Day High
1.99
Day Low
1.97
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow F98.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences is a biopharmaceutical company that develops similar therapies in the field of immunology and infectious diseases, directly competing with CytoMed's product lines.
AMGEN
AMGN
Mkt Cap177.47B
Amgen focuses on human therapeutics, including treatments in areas that overlap with CytoMed's research in immune modulation and targeted therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, particularly in monoclonal antibodies, a field that competes with CytoMed's biologic therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals engages in developing and commercializing therapies for treating cystic fibrosis and other serious diseases, competing in the specialty biotech sector alongside CytoMed.
Biogen
BIIB
Mkt Cap33.5B
Biogen's focus on advanced biologics for neurological diseases and its expansion into immunology make it a direct competitor in the biopharmaceutical space.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie operates in similar therapeutic areas including immunology and oncology, directly competing with CytoMed's research and development efforts.
Merck &
MRK
Mkt Cap323.59B
Merck is a global healthcare company that develops prescription medicines and biologic therapies, competing across several of CytoMed's key areas.
Pfizer
PFE
Mkt Cap163.88B
Pfizer's broad range of biopharmaceutical products and its investment in biotechnology research make it a competitor in multiple therapeutic areas covered by CytoMed.
Novartis
NVS
Mkt Cap244.62B
Novartis is a global healthcare company that produces drugs in nearly all of the same categories as CytoMed, making it a significant competitor.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca operates globally in biopharmaceuticals, focusing on several of the same disease areas as CytoMed, particularly in oncology and respiratory diseases.

About

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Show more...
CEO
Employees
28
Country
SG
ISIN
SGXZ17669631
WKN
000A3D4GB

Listings